Zepbound vs Wegovy in Detroit, MI: How They Compare
Zepbound vs Wegovy in Detroit, MI: How They Compare
Zepbound (tirzepatide) and Wegovy (semaglutide) are both FDA-approved once-weekly injections for chronic weight management. They are the two medicines adults in Detroit and across Michigan ask about most. This guide explains how they differ so you can have a more useful conversation with a physician. It is not a recommendation for either one.
Medically reviewed by Dr. Diala Alatassi, MD, DABIM, DABOM, FACP. Last reviewed: October 2026.
Next step: Take the 2-minute eligibility quiz to see whether you qualify. There is no charge and no credit card is required. If you move forward, the video consultation is $99.
Side by side
| Zepbound | Wegovy | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| How it works | Activates GIP and GLP-1 receptors | Activates GLP-1 receptors |
| Form | Once-weekly injection | Once-weekly injection |
| Typical start | 2.5 mg weekly, raised in 2.5 mg steps about every 4 weeks | 0.25 mg weekly, raised about every 4 weeks |
| Maintenance doses | 5, 10 or 15 mg weekly | 1.7 mg or 2.4 mg weekly |
| Other labeled uses | Moderate-to-severe obstructive sleep apnea in adults with obesity | Lowers risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight |
| Our guide | Zepbound in Detroit | Wegovy in Detroit |
What a head-to-head trial found
In SURMOUNT-5, a 72-week study of 751 adults with obesity who did not have type 2 diabetes, people taking tirzepatide lost about 20.2% of their body weight on average, compared with about 13.7% for people taking semaglutide. These are group averages. Individual results vary a great deal, and the trial does not mean one medicine is the right choice for every person.
What they share
Both medicines commonly cause nausea, diarrhea, vomiting, constipation and abdominal discomfort, especially while the dose is rising. Both carry a boxed warning about thyroid C-cell tumors seen in rodents, and neither should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both can rarely cause pancreatitis or gallbladder problems, and neither is for use in pregnancy.
What can tip the decision
- Your health conditions. Sleep apnea or established heart disease may point toward the medicine labeled for it.
- Side effects and tolerance. Some people tolerate one better than the other.
- Insurance and cost. Plans often prefer one product, and cash prices and manufacturer programs differ. See our guide to manufacturer savings programs and cost guide.
- Supply. Availability of specific doses at your pharmacy can change.
FAQs
Which one works better?
On average, tirzepatide produced more weight loss than semaglutide in the one large head-to-head trial above. That does not predict your own result, and the better medicine for you also depends on your health history, side effects and cost.
Can I switch from one to the other?
Sometimes. Switching is a physician decision that depends on your current dose, side effects and goals, so do not change on your own.
Does TeleSlim Clinic prescribe both?
Yes, when a Michigan-licensed physician finds either appropriate after a video evaluation. Prescriptions go to the pharmacy you choose, and TeleSlim Clinic does not dispense medication or offer compounded GLP-1 medications.
Related guides
- Zepbound (tirzepatide)
- Wegovy (semaglutide)
- Weekly injection vs daily pill
- Weight loss medication cost in Detroit, MI
- Weight loss medications in Detroit, MI
- Online weight loss doctor in Detroit, MI
Sources and further reading
- Zepbound (tirzepatide) prescribing information, DailyMed (U.S. National Library of Medicine)
- Wegovy (semaglutide) prescribing information, DailyMed (U.S. National Library of Medicine)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021
Links open third-party sites. Prescribing information is the authoritative source for approved uses, dosing and safety.
Meet your physician
Dr. Diala Alatassi, MD, DABIM, DABOM, FACP is Chief Medical Officer of TeleSlim Clinic. She is board-certified in Internal Medicine and Obesity Medicine and is licensed to practice in Michigan. All TeleSlim Clinic visits are conducted by video with a board-certified physician.
Take the 2-minute eligibility quiz to see whether you qualify. If you move forward, the video consultation is $99 and monthly physician follow-up is $99.
This page is general education, not medical advice. Whether a medication is appropriate is a decision made by a physician after an evaluation. Individual results vary.



